Test for the determination of human autoantibodies against the protein CASPR2 to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
This test provides the quantitative determination of beta-amyloid 1-42 (Aβ1-42). Its use is recommended in combination with a test for the determination of beta-amyloid 1-40 (Aβ1-40), for the determination of cerebral amyloidosis.
This test provides the quantitative determination of beta-amyloid 1-40 (Aβ1-40). Its use is recommended in combination with a test for the determination of beta-amyloid 1-42 (Aβ1-42), for the determination of cerebral amyloidosis.
This test detects human antibodies of the immunoglobulin class IgG against aquaporin-4 (AQP4), to support the diagnosis of demyelinating diseases of the central nervous system.
Test for the determination of human autoantibodies against CV2 (CRMP5) to support the diagnosis of paraneoplastic neurological syndromes with a high-risk phenotype.
Test for the determination of human autoantibodies against neurofascin 186 (NF186), to support the diagnosis of autoimmune nodopathy.
Test for the determination of human autoantibodies This against neurofascin 155 (NF155), to support the diagnosis of autoimmune nodopathy.
Test for the determination of human autoantibodies against metabotropic glutamate receptor 5 (mGluR5), to support the diagnosis of autoimmune encephalitis, particularly limbic forms sometimes associated with Hodgkin lymphoma (Ophelia syndrome).
Subscribe to our newsletter to be always updated.